Philip Falcone
Analyst · B. Riley FBR. Your line is now open
Thanks, Garrett and good afternoon everyone. Thank you for joining us today. We are going to change things up a bit on how we present this quarter and moving forward. I am going to deliver a more high-level overview of the quarter and focus on our strategic goals and vision from both a near-term and longer term perspective. Our CFO, Mike Sena will then discuss the quarter’s financial performance in more detail and then we will open up the call for your Q&A. Overall, we had a very busy fourth quarter across the portfolio and for that matter, an extremely active and transformative 2018. In the fourth quarter alone, our construction segment performed well and we successfully acquired GrayWolf Industrial in late November. One of our Pansend Life Science investments, MediBeacon, received breakthrough device designation from the FDA for its real-time kidney function measurement system. This means that the FDA will be working with the company to provide an expedited regulatory review process providing greater potential for meaningful upside from the investment. Our broadcasting segment continues to expand its operations completing strategic station acquisitions in key markets. We recaptured another of our reinsurance treaties and booked a significant gain in the quarter and added over $2.4 billion of assets to our insurance investment portfolio with the Humana transaction. We also completed the refinancing of our senior secured debt and with new senior secured notes, extended our maturity to the end of 2021. And we announced that we are seeking strategic alternatives, including possible sale of Global Marine in our Marine Services segment. Specifically, in terms of the strategic alternatives process for Global Marine, the process remains ongoing and we expect it will continue to take time as we pursue multiple paths to maximize value. If and when we receive an appropriate price for Global and have a definitive agreement, we will certainly share that information. As we noted previously, proceeds from any sale would be utilized to reduce debt at the HC2 level. Beyond that, we cannot comment further or answer questions at this time given it is still an active and ongoing process. As we look at 2019 and beyond in regard to our portfolio, I want to take a few minutes to speak to the further transformation of our business that will position us to bribe shareholder value over the longer term. Our longer term strategy is hybrid. We have built a portfolio of strong cash generating businesses over the years led by our construction and insurance businesses and they will be an important driver for us in the near-term while we focus on delivering HC2. Beyond our cash generating segments and focusing on the mid to longer term, we have our growth engine that is our broadcasting segment and the ability to unlock significant value at our Pansend Life Sciences segment. First and foremost, among our cash flow generating segments is construction anchored by DBM. The team there has done an excellent job in building their business, winning new contracts and filling up its robust backlog and in 2018, it generated adjusted EBITDA of approximately $61 million. It has been doing a great job working toward completion on large projects such as the new LA Rams/Chargers stadium in Inglewood, which is slated to open in 2020 as well as Loma Linda Hospital near San Bernardino and Google Bayview just outside of San Jose. Importantly, DBM has been a stalwart investment for HC2 and a great example of the value we have been able to create over the past 5 years. In addition to a successful 2018, DBM also had a strong start to 2019 with a couple of major midsize project wins for the business. As we noted on the prior call, our objective at DBM was to target a backlog mix that focuses more on the small to midsize projects as we work off the larger LA Rams type projects, which tend to create more lumpiness and tie up more working capital. That said, we will still pursue large projects that we believe we can execute on profitably. Ultimately, this approach that we are taking today will provide more stability in the business. Our initiative to further expand the DBM business and our push to our goal of $1 billion revenue and $100 million adjusted EBITDA entity continued with the acquisition of GrayWolf late last year. This acquisition will expand our construction segment capabilities into heavy maintenance and repair, which should minimize some of the cyclicality inherent in commercial construction given GrayWolf’s longer term recurring contracts. It also provides a potential opportunity for cross-selling which ultimately gives us another opportunity at building stickier longer term relationships in recurring streams of revenue. Overall, we expect DBM to continue to be a major driver of consistent strong cash flow generation for HC2 for years to come. In addition, we have significantly built up our insurance segment over the past several quarters most notably through our recent acquisition of Humana’s long-term care business, which increased our insurance asset base to over $4 billion, a 169% increase from year end 2017. Total adjusted capital increased as well and was approximately $289 million at year end. As a reminder, HC2 receives an investment management fee from the investment portfolio, which provides us with the strong recurring cash flow stream, while the portfolio also has the potential to achieve additional positive returns on investment. Also as a result of the transaction with Human, there were significant NOLs generated which will shield the insurance subsidiary from future tax payments for the next few years. Mike will touch upon that in more detail in his remarks. Two of our other businesses that are also positively generating cash are our energy and telecom segments. While we expect telecom’s contribution to slow and most likely run off in the coming years, energy remains a solid little contributor which has the potential for significant upside over the longer term. Turning to Marine Services, we were certainly disappointed with its performance during the fourth quarter. Specifically, we can point to several discrete timing shifts and other unanticipated events that impacted adjusted EBITDA, which Mike will address in his remarks. The challenges at Marine in the fourth quarter will also underscore one of the advantages of our diversified strategy. When one segment is challenged, our other segments can be an effective counterbalance. Even with the decline in Global Marine, our core operating subsidiaries adjusted EBITDA was essentially flat year-over-year. Furthermore, we remained confident in the Marine Services cash-generating abilities given their significant backlog at the end of 2018 and we are continuing as I stated earlier to engage in the strategic alternative process for the company. If I talk about our strategy being a hybrid and the second part of the strategy is the significant long-term potential for our growth investments. First, as I have discussed on previous calls regarding our strategy for the broadcasting business, we have invested in and acquired over the last 1.5 years, a very strong and diversified portfolio of stations and licenses. To that point as of March 6, 2019, broad cast portfolio, including completed and pending transactions comprised 176 operational television stations, including 15 full power, 58 Class A and 103 low power TV stations. We also owned 385 silent licenses and construction permits leaving us in an enviable position to grow for the long-term. We now reached approximately 60% of the U.S. population having added key MSAs in the fourth quarter and our longer term goal by lighting up many of our silent licenses continues down the path of reaching our 80% of the population with our over-the-air network. As people continue to cut the cord, broadcasting has the potential to become a much more attractive alternative distribution option as we build out the platform. In addition, with the advent of new technology we anticipate the ability to broadcast directly to mobile devices as another opportunity for us to realize moving forward. As we look into 2019, we are beginning to approach the homestretch of our overall investment plan for broadcasting. We will look to add broadcasting assets where necessary to further build out our platform and the reminder of our investment efforts will be focused on upgrading our technology and infrastructure. And as we integrate the assets, we have acquired we should be able to wind efficiencies and thus create a more streamlined platform. We do want to note given our ongoing investment effort and expansion that it may take a little longer than initially expected to become run-rate adjusted EBITDA breakeven. We expect the growth trajectory and value of broadcasting to become readily apparent once the platform is fully built out. With the large amount of broadcasting platform expenses being fixed, once we have completed our investment program, we will be squarely positioned from margin expansion and profitability in the mid to long-term. This will then provide us with significant free cash flow per year. We believe there is significant amount of value to be unlocked at broadcasting and as we complete our build out that will become much more apparent to the investment community. Turning to our Pansend Life Sciences segment, we completed the successful monetization of BeneVir during 2018 driving significant value for shareholders. By structuring the sale the way we did, HC2 will be able to receive up to approximately $140 million net additional cash payments should BeneVir secure FDA, EU and Japanese approvals and over the long-term an additional $370 million net from sales milestones. But as we look forward, we are very excited about opportunities for two of our other Pansend portfolio companies that I would like to discuss. First, MediBeacon, which has developed a real-time kidney function measurement system recently, was granted breakthrough device designation by the FDA, which accelerates the FDA approval process and validates how important and necessary to the market MediBeacon technology is in addressing patient needs. We have invested 24 million in MediBeacon thus far. We are very well positioned to attract significant value from that investment via monetization. We will continue to keep you apprised of the progress of MediBeacon in future quarters. The second company, R2 Dermatology, has already received FDA approvals in 2016 and 2017 for its skin lightening and evening product using cold technology, which we have noted in previous calls. This is an investment where we have put to work just over 26 million and own a majority stake in the company. We are very excited about its significant potential in both the U.S. and Asian markets. R2 is currently looking to position the product for commercialization to various strategic partnerships. Hence we continue to evaluate opportunities to properly commercialize R2 and position it to generate growing and sizable profits over the mid to long term. Let me briefly touch on our balance sheet. While we are clearly dissatisfied with the outcome of the refinancing, it unfortunately was a necessary step that we had to take. As the Chairman and CEO, my priorities are to de-lever and improve upon on our execution of the business and I am confident we will accomplish this. While our near-term and top priority is reducing debt at HC2, we will be remiss if we did not highlight the strong portfolio of businesses that we have built. This will no doubt help us win over the long-term with strong existing cash flows coming from our construction insurance businesses and potential meaningful value creation at Global Marine, broadcasting and life sciences we are positioned well to unlock significant value for our shareholders over time. With that, I will now turn the call over to our CFO, Mike Sena who will discuss some of our fourth quarter and full year 2018 financial highlights. Mike?